Use the hyperlinks, where available to access additional clinical trial information.
Phase I/II clinical trial to assess the safety and biological efficacy of treatment with virus-specific, cytotoxic T-lymphocytes from partially matched third-party unrelated donors, in stem cell transplant patients with viral reactivation unresponsive to standard therapy (Other ID's: U1111-1140-8324 )
Other Non-Commercial Sponsor
Western Sydney Local Health Districit
To assess the safety and efficacy of providing partially HLA matched, third party donor-derived, EBV/CMV/adenovirus-specific cytotoxic t-cells, to allogeneic stem cell/marrow transplant patients who have developed post-transplant viral infections unresponsive to standard therapy. It is hypothesised that virus-specific t-cells infusions will improve or restore the virus-specific immunity of the transplant patient in a safe manner without precipitating graft versus host disease.